Immunotherapy for a patient with high-grade glioblastoma

Close metadata

Recommended articles:

Early chemotherapy between surgery and radiotherapy in grade 4 gliomas. P.A. Herzen Journal of Oncology. 2024;(5):12-17

Immune checkpoint inhibitors as a component of perioperative therapy in patients with resectable esophageal and cardioesophageal junction cancer. P.A. Herzen Journal of Oncology. 2024;(5):62-68

Antigen receptors in the development of CAR-T cells for glioblastoma immunotherapy. P.A. Herzen Journal of Oncology. 2024;(6):91-95

The choice of radiotherapy dose fractionation regimen for grade 4 gliomas depending on the status of MGMT. P.A. Herzen Journal of Oncology. 2025;(1):13-18

Patients with long-term survival in malignant gliomas after photodynamic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):54-61

Choice of fractionation regimen for Grade IV gliomas depending on rapid early progression. Burdenko's Journal of Neurosurgery. 2024;(5):23-29

Local cytokine profile of the endometrium in patients with repeated implantation failures and its pharmacological correction by the secretome of peripheral blood mononuclear cells. Russian Journal of Human Reproduction. 2024;(5):46-54

A Novel Rat Glioblastoma 101/8 Model: A Comparative PET-CT Study with C6 Rat model. Burdenko's Journal of Neurosurgery. 2024;(6):54-62

Claudin-18.2 and gastric cancer: from physiology to carcinogenesis. Russian Journal of Archive of Pathology. 2024;(6):92-99

Possibilities of using bacterial lysates in the treatment and prevention of upper respiratory tract infectious diseases. Russian Rhinology. 2024;(4):314-322

High-grade gliomas account for 35 to 46% of all central nervous system tumors. Despite combination therapy, the overall 5-year survival rate does not exceed 10%. The emergence of innovative immunotherapeutic strategies was the beginning of a new direction in the treatment of this category of patients. The paper describes a clinical case of a patient with the third recurrent glioblastoma multiforme (GBM). The immunotherapy protocol included the combined administration of an autologous dendritic cell-based vaccine and repeated intrathecal/intraventricular injections of donor allogeneic immunocompetent cells for 3 years. The patient is in remission without any therapy within 13.3 years after starting immunotherapy. No side effects were observed. Thus, immunotherapy may be an option for the treatment of patients with high-grade malignant gliomas refractory to conventional therapy and deserves further study.

Keywords:

glioblastoma

immunotherapy

dendritic vaccine

allogeneic adoptive cell therapy

Authors:

Dolgopolov I.S.

Tver State Medical University, Ministry of Health of Russia

Rykov M.Yu.

Tver State Medical University, Ministry of Health of Russia;
N.A. Semashko National Research Institute of Public Health

Mentkevich G.L.

Tver State Medical University, Ministry of Health of Russia

Chkadua G.Z.

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Ryzhova M.V.

Burdenko Neurosurgical Center

ORCID: 0000-0001-7206-6365

Received:

20.01.2022

Accepted:

31.05.2022

List of references:

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-820. https://doi.org/10.1007/s00401-016-1545-1
Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, Villano JL. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1985-1996. https://doi.org/10.1158/1055-9965.EPI-14-0275
Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, et al. ALA-Glioma Study Group. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. 2008;62(3):564-576; discussion 564-576. https://doi.org/10.1227/01.neu.0000317304.31579.17
Cui Y, Tha KK, Terasaka S, Yamaguchi S, Wang J, Kudo K, Xing L, Shirato H, Li R. Prognostic imaging biomarkers in glioblastoma: development and independent validation on the basis of multiregion and quantitative analysis of MR images. Radiology. 2016;278(2):546-553. https://doi.org/10.1148/radiol.2015150358
Ellingson BM. Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics. Curr Neurol Neurosci Rep. 2015;15(1):506. https://doi.org/10.1007/s11910-014-0506-0
Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee ShU. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev. 2017;18(1):3-9. https://doi.org/10.22034/APJCP.2017.18.1.3
Witthayanuwat S, Pesee M, Supaadirek C, Supakalin N, Thamronganantasakul K, Krusun S. Survival analysis of glioblastoma multiforme. Asian Pac J Cancer Prev. 2018;19(9):2613-2617. https://doi.org/10.22034/APJCP.2018.19.9.2613
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. https://doi.org/10.1056/NEJMoa043330
Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. 2019;21(suppl 5):1-100. https://doi.org/10.1093/neuonc/noz150
Auffinger B, Thaci B, Nigam P, Rincon E, Yu Cheng, Lesniak MS. New therapeutic approaches for malignant glioma: in search of the Rosetta stone. F1000 Med Rep. 2012;4:18. https://doi.org/10.3410/M4-18
Rolle CE, Sengupta S, Lesniak MS. Challenges in clinical design of immunotherapy trials for malignant glioma. Neurosurg Clin N Am. 2010;21(1):201-214. https://doi.org/10.1016/j.nec.2009.08.002
Chung D, Shin HJ, Hong YK. A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res. 2014;2014:326545. https://doi.org/10.1155/2014/326545
Kang X, Zheng Y, Hong W, Chen X, Li H, Huang B, Huang Z, Tang H, Geng W. Recent advances in immune cell therapy for glioblastoma. Front Immunol. 2020;11:544563. https://doi.org/10.3389/fimmu.2020.544563
Eagles ME, Nassiri F, Badhiwala J, Suppiah SA, Almenawer SA, Zadeh G, Aldape KD. Dendritic cell vaccines for high-grade gliomas. Ther Clin Risk Manag. 2018;14:1299-1313. https://doi.org/10.2147/TCRM.S135865
Pellegatta S, Eoli M, Cuccarini V, Anghileri E, Pollo B, Pessina S, Frigerio S, Servida M, Cuppini L, Antozzi C, et al. Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide. Oncoimmunology. 2018;7(4):e1412901. https://doi.org/10.1080/2162402X.2017.1412901
Frederico SC, Hancock JC, Brettschneider EES, Ratnam NM, Gilbert MR, Terabe M. Making a cold tumor hot: the role of vaccines in the treatment of glioblastoma. Front Oncol. 2021;11:672508. https://doi.org/10.3389/fonc.2021.672508
Poon CC, Sarkar S, Yong VW, Kelly JJP. Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis. Brain. 2017;140(6):1548-1560. https://doi.org/10.1093/brain/aww355
Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother. 2008;57(1):123-131. https://doi.org/10.1007/s00262-007-0336-x
Zagzag D, Salnikow K, Chiriboga L, Yee H, Lan L, Ali MA, Garcia R, Demaria S, Newcomb EW. Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest. 2005;85(3):328-341. https://doi.org/10.1038/labinvest.3700233
Almuhaisen G, Alhalaseh Y, Mansour R, Abu-Shanab A, Al-Ghnimat S, Al-Hussaini M. Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA). Brain Tumor Pathol. 2021;38(1):14-22. https://doi.org/10.1007/s10014-020-00379-7
Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S, Goldfinger D, Ng H, Irvin D, Yu JS. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 2008;68(14):5955-5964. https://doi.org/10.1158/0008-5472.CAN-07-5973
Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita M, Takahashi M, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res. 2005;11(11):4160-4167. https://doi.org/10.1158/1078-0432.CCR-05-0120
Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother. 2013;62(9):1499-1509. https://doi.org/10.1007/s00262-013-1453-3
Ruggeri L, Capanni M, Urbani F, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562);2097-2100. https://doi.org/10.1126/science.1068440
Willem C, Makanga DR, Guillaume T, Maniangou B, Legrand N, Gagne K, Peterlin P, Garnier A, Béné MC, Cesbron A, et al. Impact of KIR/HLA incompatibilities on NK cell reconstitution and clinical outcome after T cell-replete haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide. J Immunol. 2019;202(7):2141-2152. https://doi.org/10.4049/jimmunol.1801489

Close metadata